Aripiprazole 2-Month Under Review for Schizophrenia, Bipolar I Disorder

The FDA has accepted the NDA for aripiprazole 2-month, ready-to-use, long-acting injectable for schizophrenia and bipolar I disorder in adults.

Related Keywords

Johan Luthman ,Lundbeck Research Development ,Drug Administration ,New Drug Application ,Lundbeck Research ,Prescription Drug User Fee Act ,